Ironwood Poised To Move Linaclotide To Phase III In IBS-C
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With a pair of pivotal Phase III trials in chronic constipation under way, Ironwood Pharmaceuticals reported success Oct. 7 in Phase IIb testing of linaclotide in constipation-predominant irritable bowel syndrome. Partnered in the U.S. with Forest Laboratories, the firm plans to begin two pivotal Phase III trials in IBS-C by next January
You may also be interested in...
Forest’s Linaclotide, Aclidinium Ready For Phase III
Drugs for constipation and COPD could require extra marketing effort, analysts say.
Sucampo/Takeda’s Amitiza Gains IBS-C Indication
Approval expands the target population for lubiprostone by about 20 million patients, Sucampo commercial head tells “The Pink Sheet” DAILY.
Novartis Further Restricts Access To Zelnorm
Irritable bowel syndrome therapy available in U.S. only for emergencies.